Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KDS 1000

Next Previous
X
Search
Drug Profile

KDS 1000

Alternative Names: KDS-1000

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kiadis
  • Class Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 24 Aug 2021 Kiadis Pharma withdraws prior to enrolment a phase I/II trial for COVID-2019 infections (Parenteral) (NCT04797975)
  • 19 Mar 2021 Abigail Wexner Research Institute has a patent pending for a novel therapeutic, “universal donor” NK cells, to restore the patients’ NK cell numbers in USA
  • 15 Mar 2021 Kiadis Pharma in-licenses technology and intellectual property related to NK cells technology from Abigail Wexner Research Institute for treatment of COVID-2019 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top